SI-BONE, Inc.
NASDAQ•SIBN
CEO: Mr. Jeffrey W. Dunn
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2018-10-17
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Contact Information
Market Cap
$654.60M
P/E (TTM)
-38.9
41.8
Dividend Yield
--
52W High
$21.89
52W Low
$11.48
52W Range
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$52.59M+0.00%
4-Quarter Trend
EPS
-$0.10+0.00%
4-Quarter Trend
FCF
-$3.44M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Grows 20.2% Total revenue reached $200.9M in 2025, marking a $33.7M increase driven by higher U.S. case volumes and portfolio expansion.
Gross Profit Rises 21.0% Gross profit increased to $159.9M in 2025, with gross margin improving slightly to 79.6% due to favorable product mix changes.
Sales Force Significantly Expanded U.S. direct sales force grew to 89 managers and 320 third-party agents by year-end 2025, supporting adoption across 140,000 procedures.
Net Loss Narrows Substantially Net loss decreased to $18.9M in 2025 from $30.9M in 2024, reflecting increased revenues and improved operational leverage.
Risk Factors
Continued Operating Losses Expected Company incurred accumulated deficit of $450.3M; expects to incur operating losses for some time, making future financing difficult.
Reimbursement Environment Uncertainty Demand relies heavily on payor coverage; uncertainty in reimbursement determinations for newer products may decrease demand and impact pricing.
Supplier Concentration Poses Risk High dependence on limited third-party suppliers, including RMS for key implants; supply disruptions could severely affect business operations.
Intense Market Competition Subject to intense competition from large medical device firms; failure to timely launch innovative products risks obsolescence and margin erosion.
Outlook
Focus on Sales Force Productivity Plans include growing specialized sales force and adding clinical support specialists to increase sales force productivity to $2.1M per manager.
Increased R&D Investment Planned Innovation focus remains strong; anticipates research and development expenses will continue to increase in the future to expand portfolio offerings.
Expanding ASC/OBL Market Access Actively engaging ASCs and OBLs, where over 33% of 2025 procedures occurred, to drive adoption and manage pricing pressures.
Managing Regulatory Compliance Must manage extensive and evolving global regulations, including EU MDR and EUDAMED requirements, requiring investment in IT infrastructure.
Peer Comparison
Revenue (TTM)
$945.90M
$857.50M
$825.37M
Gross Margin (Latest Quarter)
91.7%
79.8%
76.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AVNS | $1.16B | -16.5 | -8.9% | 13.2% |
| CMPS | $1.01B | -6.5 | -151.0% | 0.5% |
| BFLY | $1.00B | -13.0 | -36.8% | 6.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.6%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Aug 3, 2026
EPS:-$0.15
|Revenue:$55.33M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data